[go: up one dir, main page]

MX2012013613A - Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. - Google Patents

Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Info

Publication number
MX2012013613A
MX2012013613A MX2012013613A MX2012013613A MX2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A
Authority
MX
Mexico
Prior art keywords
patients
treatment
antibodies
risk
cll
Prior art date
Application number
MX2012013613A
Other languages
English (en)
Other versions
MX341463B (es
Inventor
Karl-Heinz Heider
Stilgenbauer Stephan
Zenz Thorsten
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012013613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2012013613A publication Critical patent/MX2012013613A/es
Publication of MX341463B publication Critical patent/MX341463B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención describe anticuerpos CD37, especialmente A2 y B2, para el tratamiento de pacientes con CLL, especialmente de pacientes que pertenecen a un grupo de pacientes de "alto riesgo" o "ultra-alto riesgo". Estos pacientes son pacientes refractarios al tratamiento con fludarabina o bien pacientes que portan un marcador genético que indica un pronóstico deficiente o un riesgo incrementado de fracaso de tratamiento, por ejemplo, pacientes con disfunción de TP53 o deleción del cromosoma 17p13, o pacientes después del fracaso a tratamiento anti-CD20 anterior. La habilidad de A2 y B2 para la depleción de células de CLL es alta en muestras de pacientes derivadas de pacientes con riesgo normal y con riesgo incrementado (pacientes de "alto riesgo") y claramente superior a la de rituximab y alemtuzumab.
MX2012013613A 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. MX341463B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (2)

Publication Number Publication Date
MX2012013613A true MX2012013613A (es) 2012-12-17
MX341463B MX341463B (es) 2016-08-22

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013613A MX341463B (es) 2010-07-16 2011-07-15 Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.

Country Status (15)

Country Link
US (3) US20120189618A1 (es)
EP (2) EP3252077A1 (es)
JP (2) JP2013538790A (es)
KR (1) KR20130100918A (es)
CN (2) CN105749276A (es)
AU (1) AU2011278227B2 (es)
BR (1) BR112013001012A2 (es)
CA (1) CA2799036A1 (es)
CL (1) CL2013000101A1 (es)
EA (1) EA025365B1 (es)
IL (1) IL222775A (es)
MX (1) MX341463B (es)
NZ (2) NZ603161A (es)
PH (1) PH12013500118A1 (es)
WO (1) WO2012007576A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3595721B1 (en) * 2017-03-16 2025-07-09 The General Hospital Corporation Chimeric antigen receptors targeting cd37
KR102706161B1 (ko) 2017-03-31 2024-09-19 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
BR112021006055A2 (pt) 2018-10-04 2021-07-20 Genmab Holding B.V. composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo.
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2007014278A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
BRPI0911377A8 (pt) * 2008-04-11 2017-12-05 Trubion Pharmaceuticals Inc Imunoterápico de cd7 e combinação com quimioterápico bifuncional deste
US20100135900A1 (en) * 2008-11-13 2010-06-03 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic combination therapies and uses thereof

Also Published As

Publication number Publication date
CA2799036A1 (en) 2012-01-19
EP3252077A1 (en) 2017-12-06
PH12013500118A1 (en) 2013-03-11
MX341463B (es) 2016-08-22
US20130236454A1 (en) 2013-09-12
EP2593479A1 (en) 2013-05-22
NZ703225A (en) 2016-11-25
KR20130100918A (ko) 2013-09-12
EA201201660A1 (ru) 2013-07-30
IL222775A0 (en) 2012-12-31
AU2011278227A1 (en) 2012-11-15
BR112013001012A2 (pt) 2016-05-24
CN103003309A (zh) 2013-03-27
US20120189618A1 (en) 2012-07-26
WO2012007576A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
US20150266967A1 (en) 2015-09-24
JP2017019800A (ja) 2017-01-26
CL2013000101A1 (es) 2013-12-27
EA025365B1 (ru) 2016-12-30
IL222775A (en) 2017-10-31
NZ603161A (en) 2015-02-27
AU2011278227B2 (en) 2017-03-02
CN105749276A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
PH12013500118A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
NZ574046A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MX2012010418A (es) Inhibidores syk de imidazopiridinas.
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
MY168762A (en) Certain chemical entities, compositions and methods
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
MX365054B (es) Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
MX368173B (es) Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
TN2014000337A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
AU2011338647A8 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
PH12013501242B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MA33810B1 (fr) Compositions pour traiter les nausées et vomissements à médiation centrale
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2008039409A3 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
WO2010102160A3 (en) Diagnostic method using palb2
WO2011118928A3 (ko) 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
UA116615C2 (uk) Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
SI2746404T1 (en) ANTITUM AND THERAPEUTIC EFFECTS OF THE FORMAL METHOD FOR PATIENTS WITH KRAS-MUTRIC COLORECTAL CANCER

Legal Events

Date Code Title Description
FG Grant or registration